REFERENCES
1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
2. Nguyen TD, Rahman NT, Sessa WC, Lee MY. Endothelial nitric oxide synthase (eNOS) S1176 phosphorylation status governs atherosclerotic lesion formation. Front Cardiovasc Med. 2023;10:1279868.
3. Wang K, Sun C, Zhuang H, Jiang XC, Chen Y. AFM reveals differential effects of acidification on LDL- and oxidized LDL-receptor interactions: biomechanical implications in atherogenesis. Cell Mol Biol Lett. 2025;30:32.
4. Wu J, Liu T, Xie W, Zhuo Y, Feng Y. Ox-LDL promotes M1-like polarization of macrophages through the miR-21-5p/SKP2/EP300 pathway. J Biochem Mol Toxicol. 2024;38:e23516.
5. Yashin AI, Wu D, Arbeev K, et al. Roles of interacting stress related genes in lifespan regulation: insights for translating experimental findings to humans. J Transl Genet Genom. 2021;5:357-79.
6. Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities. Trends Pharmacol Sci. 2018;39:307-25.
7. St Paul M, Saibil SD, Kates M, et al. Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy. Cell Rep Med. 2024;5:101465.
8. Almog T, Keshet R, Kandel-Kfir M, et al. Gene deletion of Interleukin-1α reduces ER stress-induced CHOP expression in macrophages and attenuates the progression of atherosclerosis in apoE-deficient mice. Cytokine. 2023;167:156212.
9. Chen R, Zhang Y, Zhao C. CHOP increases TRIB3-dependent miR-208 expression to potentiate vascular smooth muscle cell proliferation and migration by downregulating TIMP3 in atherosclerosis. Cardiovasc Drugs Ther. 2022;36:575-88.
10. Hong JG, Zheng HL, Wang P, Huang P, Gong DP, Zeng ZY. Hsa_ circ_0006867 regulates ox-LDL-induced endothelial injury via the miR-499a-3p/ADAM10 axis. Clin Hemorheol Microcirc. 2024;88:115-27.
11. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276:618-32.
12. Liu SL, Bajpai A, Hawthorne EA, et al. Cardiovascular protection in females linked to estrogen-dependent inhibition of arterial stiffening and macrophage MMP12. JCI Insight. 2019:4.
14. Lv JJ, Wang H, Zhang C, et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis. Circ Res. 2024;134:165-85.
15. Yuan Y, Fan G, Liu Y, et al. The transcription factor KLF14 regulates macrophage glycolysis and immune function by inhibiting HK2 in sepsis. Cell Mol Immunol. 2022;19:504-15.
16. Felmlee MA, Jones RS, Rodriguez-Cruz V, Follman KE, Morris ME. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev. 2020;72:466-85.
17. Tassinari M, Tanzi G, Maggiore F, et al. Molecular mechanism of thyroxine transport by monocarboxylate transporters. Nat Commun. 2025;16:4493.
18. Zhang Y, Jiang H, Dong M, et al. Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation. Cell Rep. 2024;43:114180.
19. Vellasamy DM, Lee SJ, Goh KW, et al. Targeting immune senescence in atherosclerosis. Int J Mol Sci. 2022;23:13059.
20. Zhao L, Lv X, Chen W, et al. Athero-oncology perspective: identifying hub genes for atherosclerosis diagnosis using machine learning. Front Immunol. 2025;16:1616096.
21. Zhan J, Chen Y, Liu Y, et al. IDO1-mediated AhR activation up-regulates pentose phosphate pathway via NRF2 to inhibit ferroptosis in lung cancer. Biochem Pharmacol. 2025;236:116913.
22. Zhen X, Zhang M, Hao S, Sun J. Glucose-6-phosphate dehydrogenase and transketolase: key factors in breast cancer progression and therapy. Biomed Pharmacother. 2024;176:116935.
23. Kelly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25:771-84.
24. Soto-Heredero G, Gómez de Las Heras MM, Gabandé-Rodríguez E, Oller J, Mittelbrunn M. Glycolysis-a key player in the inflammatory response. FEBS J. 2020;287:3350-69.
25. Huang SC, Everts B, Ivanova Y, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol. 2014;15:846-55.
26. Ma C, Hua Y, Yang S, et al. Wogonin attenuates atherosclerosis via KLF11-mediated suppression of PPARα-YAP1-driven glycolysis and enhancement of ABCA1/G1-mediated cholesterol efflux. Adv Sci. 2025;12:e2500610.
27. Petit PX. Cellular ATP levels alone do not reliably reflect overall mitochondrial bioenergetics or mitochondrial dysfunction in Barth syndrome. J Transl Genet Genom. 2025;9:194-206.
28. Bekkering S, van den Munckhof I, Nielen T, et al. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis. 2016;254:228-36.
29. Li M, Liu X, Yu X, Yin A, Fu X, Guan X. FBP1/HIF-1α Axis mediates macrophage metabolic reprogramming and serves as diagnostic biomarkers in atherosclerosis. Int Immunopharmacol. 2026;169:116012.
30. Wang X, Liu X, Wu W, et al. Hypoxia activates macrophage-NLRP3 inflammasome promoting atherosclerosis via PFKFB3-driven glycolysis. FASEB J. 2024;38:e23854.
31. Guo S, Li A, Fu X, et al. Gene-dosage effect of Pfkfb3 on monocyte/macrophage biology in atherosclerosis. Br J Pharmacol. 2022;179:4974-91.
32. Poels K, Schnitzler JG, Waissi F, et al. Inhibition of PFKFB3 hampers the progression of atherosclerosis and promotes plaque stability. Front Cell Dev Biol. 2020;8:581641.
33. Groh L, Keating ST, Joosten LAB, Netea MG, Riksen NP. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol. 2018;40:203-14.
34. Yuan P, Hu X, Zhou Q. The nanomaterial-induced bystander effects reprogrammed macrophage immune function and metabolic profile. Nanotoxicology. 2020;14:1137-55.
35. Kieler M, Hofmann M, Schabbauer G. More than just protein building blocks: how amino acids and related metabolic pathways fuel macrophage polarization. FEBS J. 2021;288:3694-714.
36. Galán M, Fernández-Méndez L, Núñez V, et al. cDC1s promote atherosclerosis via local immunity and are targetable for therapy. Circ Res. 2025;137:400-16.
37. Huangfu N, Li F, Wang C, et al. METTL3/RBM15 augments the stability of Kdm6b mRNA and promotes STAT1-mediated macrophage activation and atherosclerosis. Exp Mol Med. 2025;57:2916-29.
38. Chen B, Zhu L, Lin X, et al. SLC4A10 impedes atherosclerosis by diminishing IFN-γ/GZMB levels of CD8+ T cells via the MAPK pathway. Front Immunol. 2025;16:1568999.
39. Wang Y, Huang H, Liu Z, et al. Talin1 modulates the Piezo1-YAP axis to regulate endothelial cell inflammation and atherosclerosis. Cell Mol Life Sci. 2025;83:40.
40. Liang G, Wang S, Shao J, et al. Tenascin-X mediates flow-induced suppression of EndMT and atherosclerosis. Circ Res. 2022;130:1647-59.
41. Zhu X, Wang Y, Soaita I, et al. Acetate controls endothelial-to-mesenchymal transition. Cell Metab. 2023;35:1163-1178.e10.
42. Wang X, Abraham S, McKenzie JAG, et al. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature. 2013;499:306-11.
43. Liuizė A, Mongirdienė A. TGF-β isoforms and GDF-15 in the development and progression of atherosclerosis. Int J Mol Sci. 2024;25:2104.
44. Guo S, Zhou Y, Xie X. Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects. Biomed Pharmacother. 2022;155:113775.
45. Chen PY, Qin L, Li G, et al. Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis. Nat Metab. 2019;1:912-26.
47. Wang Y, Zang J, Liu C, Yan Z, Shi D. Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis. Front Immunol. 2022;13:835671.
48. Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol. 2019;15:123-34.
49. Tsiogka A, Gregoriou S, Stratigos A, et al. The impact of treatment with IL-17/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis: a systematic review. Biomedicines. 2023;11:318.
50. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131:677-87.
51. Ryu H, Chung Y. Regulation of IL-17 in atherosclerosis and related autoimmunity. Cytokine. 2015;74:219-27.
52. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605-13.
53. Wu TJ, Chang SL, Lin CY, et al. IL-17 Facilitates VCAM-1 production and monocyte adhesion in osteoarthritis synovial fibroblasts by suppressing miR-5701 synthesis. Int J Mol Sci. 2022;23:6804.
54. Chen J, Dai AX, Tang HL, et al. Increase of ALCAM and VCAM-1 in the plasma predicts the Alzheimer’s disease. Front Immunol. 2022;13:1097409.
55. Shi TY, Wen XH, Meng J, Lu YW. Effect of IL-17 on pulmonary artery smooth muscle cells and connective tissue disease-associated pulmonary arterial hypertension. Immun Inflamm Dis. 2024;12:e1243.
56. Chen C, Zhang Q, Liu S, et al. IL-17 and insulin/IGF1 enhance adhesion of prostate cancer cells to vascular endothelial cells through CD44-VCAM-1 interaction. Prostate. 2015;75:883-95.
57. Singh A, Kraaijeveld AO, Curaj A, et al. CCL18 aggravates atherosclerosis by inducing CCR6-dependent T-cell influx and polarization. Front Immunol. 2024;15:1327051.
58. Wang J, Kang Z, Liu Y, Li Z, Liu Y, Liu J. Identification of immune cell infiltration and diagnostic biomarkers in unstable atherosclerotic plaques by integrated bioinformatics analysis and machine learning. Front Immunol. 2022;13:956078.
59. van Duijn J, Kritikou E, Benne N, et al. CD8+ T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T-cell responses. Cardiovasc Res. 2019;115:729-38.
60. Vos WG, van Os BW, den Toom M, et al. T cell specific deletion of Casitas B lineage lymphoma-b reduces atherosclerosis, but increases plaque T cell infiltration and systemic T cell activation. Front Immunol. 2024;15:1297893.
61. Liu X, Li L, Yin Y, Zhang L, Wang W. Single-cell transcriptomic, transcriptomic, and metabolomic characterization of human atherosclerosis. Ann Transl Med. 2022;10:1215.
62. Wang Y, Zou Y, Jiang Q, et al. Ox-LDL-induced CD80+ macrophages expand pro-atherosclerotic NKT cells via CD1d in atherosclerotic mice and hyperlipidemic patients. Am J Physiol Cell Physiol. 2024;326:C1563-72.
63. Whitman SC, Rateri DL, Szilvassy SJ, Yokoyama W, Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol. 2004;24:1049-54.
64. Nour-Eldine W, Joffre J, Zibara K, et al. Genetic depletion or hyperresponsiveness of natural killer cells do not affect atherosclerosis development. Circ Res. 2018;122:47-57.
65. Zernecke A. Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol. 2015;35:763-70.
66. Liu D, Zhao J, Li L, et al. CD73: agent development potential and its application in diabetes and atherosclerosis. Front Immunol. 2024;15:1515875.
67. McAlpine CS, Kiss MG, Rattik S, et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature. 2019;566:383-7.
68. Keeter WC, Moriarty AK, Galkina EV. Role of neutrophils in type 2 diabetes and associated atherosclerosis. Int J Biochem Cell Biol. 2021;141:106098.
69. Zhang M, Montroy J, Sharma R, et al. The effects of biological sex on sepsis treatments in animal models: a systematic review and a narrative elaboration on sex- and gender-dependent differences in sepsis. Crit Care Explor. 2021;3:e0433.
70. Dileepan KN, Raveendran VV, Sharma R, et al. Mast cell-mediated immune regulation in health and disease. Front Med. 2023;10:1213320.
71. Lin Y, Wang J, Bu F, et al. Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis. Gut Microbes. 2025;17:2452229.
72. Jiang F, Chen Q, Wang W, Ling Y, Yan Y, Xia P. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1. J Hepatol. 2020;72:156-66.
73. Páramo JA, Cenarro A, Civeira F, Roncal C. Extracellular vesicles in atherosclerosis: current and forthcoming impact. Clin Investig Arterioscler. 2025;37:100718.
74. Jiapaer Z, Li C, Yang X, et al. Extracellular non-coding RNAs in cardiovascular diseases. Pharmaceutics. 2023;15:155.
75. Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, pyroptosis, and necroptosis-Oh My! J Mol Biol. 2022;434:167378.
76. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin. 2005;37:719-27.
77. Opdenbosch N, Lamkanfi M. Caspases in cell death, inflammation, and disease. Immunity. 2019;50:1352-64.
78. Wei X, Xie F, Zhou X, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022;19:971-92.
79. Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22:550-9.
80. Yin Z, Zhang J, Shen Z, Qin JJ, Wan J, Wang M. Regulated vascular smooth muscle cell death in vascular diseases. Cell Prolif. 2024;57:e13688.
81. Fan X, Han J, Zhong L, et al. Macrophage-derived GSDMD plays an essential role in atherosclerosis and cross talk between macrophages via the mitochondria-STING-IRF3/NF-κB axis. Arterioscler Thromb Vasc Biol. 2024;44:1365-78.
82. Jiang X, Ma C, Gao Y, et al. Tongxinluo attenuates atherosclerosis by inhibiting ROS/NLRP3/caspase-1-mediated endothelial cell pyroptosis. J Ethnopharmacol. 2023;304:116011.
83. Pan X, Xu H, Ding Z, et al. Guizhitongluo tablet inhibits atherosclerosis and foam cell formation through regulating Piezo1/NLRP3 mediated macrophage pyroptosis. Phytomedicine. 2024;132:155827.
84. Zeng W, Wu D, Sun Y, et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages. Sci Rep. 2021;11:19305.
85. Chen R, Zhang H, Tang B, et al. Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9:130.
86. Zhou Y, Zhou H, Hua L, et al. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis. Free Radic Biol Med. 2021;171:55-68.
87. Qiu Y, Shi YN, Zhu N, et al. A lipid perspective on regulated pyroptosis. Int J Biol Sci. 2023;19:2333-48.
88. Schmacke NA, O’Duill F, Gaidt MM, et al. IKKβ primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network. Immunity. 2022;55:2271-2284.e7.
89. Lv Y, Jiang Z, Zhou W, et al. Low-shear stress promotes atherosclerosis via inducing endothelial cell pyroptosis mediated by IKKε/STAT1/NLRP3 pathway. Inflammation. 2024;47:1053-66.
90. Coll RC, Schroder K, Pelegrín P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022;43:653-68.
91. Tall AR, Bornfeldt KE. Inflammasomes and atherosclerosis: a mixed picture. Circ Res. 2023;132:1505-20.
92. Hou C, Jiang X, Sheng W, et al. Xinmaikang (XMK) tablets alleviate atherosclerosis by regulating the SREBP2-mediated NLRP3/ASC/Caspase-1 signaling pathway. J Ethnopharmacol. 2024;319:117240.
93. Vieira CP, Fortmann SD, Hossain M, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020;5:137230.
94. Lu QB, Wan MY, Wang PY, et al. Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFκB/mTOR/P70S6K signaling cascade. Redox Biol. 2018;14:656-68.
95. Francis GA. The greatly under-represented role of smooth muscle cells in atherosclerosis. Curr Atheroscler Rep. 2023;25:741-9.
96. He X, Bai Q, Zhang X, Zhang L. MgCl2 attenuates ox-LDL-induced vascular smooth muscle-derived foam cells pyroptosis by downregulating the TLR4/NF-κB Signaling pathway. Biol Trace Elem Res. 2023;201:5242-56.
97. Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev Clin Pharmacol. 2015;8:189-99.
98. Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: looking beyond LDL regulation. Eur J Clin Invest. 2021;51:e13459.
99. Peng S, Xu LW, Che XY, et al. Atorvastatin inhibits inflammatory response, attenuates lipid deposition, and improves the stability of vulnerable atherosclerotic plaques by modulating autophagy. Front Pharmacol. 2018;9:438.
100. Guo C, Chi Z, Jiang D, et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity. 2018;49:842-856.e7.
101. Bodapati AP, Hanif A, Okafor DK, et al. PCSK-9 inhibitors and cardiovascular outcomes: a systematic review with meta-analysis. Cureus. 2023;15:e46605.
102. Feng X, Chen W, Ni X, et al. Metformin, macrophage dysfunction and atherosclerosis. Front Immunol. 2021;12:682853.
103. Liu X, Guo JW, Lin XC, et al. Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms. Eur Heart J. 2021;42:4847-61.
104. Bao Q, Zhang B, Zhou L, et al. CNP ameliorates macrophage inflammatory response and atherosclerosis. Circ Res. 2024;134:e72-91.
105. Li W, Li Y, Kang J, et al. 4-octyl itaconate as a metabolite derivative inhibits inflammation via alkylation of STING. Cell Rep. 2023;42:112145.
106. You Y, Bao WL, Zhang SL, et al. Sorting nexin 10 mediates metabolic reprogramming of macrophages in atherosclerosis through the lyn-dependent TFEB signaling pathway. Circ Res. 2020;127:534-49.
107. Ku EJ, Kim BR, Lee JI, et al. The anti-atherosclerosis effect of anakinra, a recombinant human interleukin-1 receptor antagonist, in apolipoprotein E knockout mice. Int J Mol Sci. 2022;23:4906.
108. Yang M, Lv H, Liu Q, et al. Colchicine alleviates cholesterol crystal-induced endothelial cell pyroptosis through activating AMPK/SIRT1 pathway. Oxid Med Cell Longev. 2020;2020:9173530.
109. Rahmani S, Roohbakhsh A, Pourbarkhordar V, Hayes AW, Karimi G. Melatonin regulates mitochondrial dynamics and mitophagy: cardiovascular protection. J Cell Mol Med. 2024;28:e70074.
110. Cong L, Liu X, Bai Y, et al. Melatonin alleviates pyroptosis by regulating the SIRT3/FOXO3α/ROS axis and interacting with apoptosis in atherosclerosis progression. Biol Res. 2023;56:62.
111. Wu R, Sun F, Zhang W, Ren J, Liu GH. Targeting aging and age-related diseases with vaccines. Nat Aging. 2024;4:464-82.
